<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04866654</url>
  </required_header>
  <id_info>
    <org_study_id>NBK132/1/2020</org_study_id>
    <nct_id>NCT04866654</nct_id>
  </id_info>
  <brief_title>Radiation Free Chemotherapy for Early Hodgkin Lymphoma</brief_title>
  <acronym>RAFTING</acronym>
  <official_title>Radiation-Free Therapy for the Initial Treatment of Good Prognosis Early Non-bulky HL, Defined by a Low Metabolic Tumor Volume and a Negative Interim PET After 2 Chemotherapy Cycles- RAFTING</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Gdansk</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Gdansk</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of the present study will provide information on short-term safety and efficacy&#xD;
      of a iPET and MTV-adapted therapeutic strategy, aimed to assess the feasibility and safety on&#xD;
      immediate disease control of a standard ABVD chemotherapy without any further treatment in&#xD;
      patients with a very low risk or treatment failure. A second very important endpoint will be&#xD;
      the efficacy of INRT &quot;on demand&quot; followed by Nivolumab maintenance for one year to rescue&#xD;
      patients failing first-line treatment and relapsing with the pattern of &quot;limited relapse&quot; in&#xD;
      terms of 3-Y failure from 2 relapse (FF2R). Patients entering into the study will be also&#xD;
      asked to participate to a long-term follow up study (beyond ten years) to assess the&#xD;
      prevalence of late-onset cardiovascular effects and secondary tumors in the cohort of&#xD;
      patients enrolled in the experimental and control arm of the study. An exploratory endpoint&#xD;
      has been also added such as the role of Minimal Residual Disease (MRD) detection by cell-free&#xD;
      DNA assay on peripheral blood samples obtained during treatment in predicting long-term&#xD;
      disease control.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 4, 2021</start_date>
  <completion_date type="Anticipated">July 2, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy exploration in terms of 3-Y PFS of chemotherapy alone</measure>
    <time_frame>During follow-up (36 months) after the end of treatment</time_frame>
    <description>To explore the efficacy, in terms of 3-Y PFS of chemotherapy alone in low-risk early-stage I-IIA HL patients, defined by both a low MTV and a negative interim PET after 2 courses of ABVD</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy exploration in terms of 3-Y PFS of chemotherapy plus Nivolumab</measure>
    <time_frame>During follow-up (36 months) after the end of treatment</time_frame>
    <description>To explore the efficacy in terms of 3-Y PFS of CMT plus Nivolumab in high-risk early-stage (I-IIA) HL (eHL), defined either by a positive PET- 2 or a high baseline MTV or both</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy exploration in terms of 3-Y freedom from 2nd treatment failure (3-Y FF2TF) of chemotherapy followed by radiotherapy &quot;on demand&quot; plus Nivolumab maintenance</measure>
    <time_frame>During follow-up (36 months) after the end of treatment</time_frame>
    <description>To explore the efficacy in terms of 3-Y freedom from 2nd treatment failure (3-Y FF2TF) of chemotherapy followed by radiotherapy &quot;on demand&quot; plus Nivolumab maintenance in patients relapsing with the pattern of &quot;limited relapse&quot; (see below) for the entire group (relapsed and non-relapsed) of low-risk patients (with low MTV and negative PET- 2) high-risk early-stage (I-IIA) HL (eHL), defined either by a positive PET- 2 or a high baseline MTV or both</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety exploration in terms of 3-Y OS of a treatment with chemotherapy alone</measure>
    <time_frame>During follow-up (36 months) after the end of treatment</time_frame>
    <description>To explore the safety in terms of 3-Y OS of a treatment with chemotherapy alone in low-risk early-stage (I-IIA) HL patients, defined by a low Metabolic Tumor Volume negative interim PET after 2 ABVD courses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation the ability of cell-free DNA (cfDNA) assay</measure>
    <time_frame>During follow-up (36 months) after the end of treatment</time_frame>
    <description>To evaluate the ability of cell-free DNA (cfDNA) assay to detect an impending relapse during follow-up in low-risk patients treated with chemotherapy alone�k�</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab, total dose 5760 mg milligram</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab 10 MG/ML</intervention_name>
    <description>Nivolumab, 100 mg, 10 mg/ml</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients aged 18-60.&#xD;
&#xD;
          -  Treatment-naïve, HL patients with Ann Arbor stage I or II A non-bulky disease&#xD;
             stratified according to modified EORTC Criteria (refer to Appendix A);&#xD;
&#xD;
          -  Patients must have histologically confirmed classical HL according to the current&#xD;
             World Health Organization Classification (nodular sclerosis, mixed cellularity,&#xD;
             lymphocytes rich, lymphocytes depleted, or classical HL NOS [not otherwise specified];&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Hemoglobin must be &gt; 8 gr./dL&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/μL&#xD;
&#xD;
          -  Platelet count ≥ 100,000/μL&#xD;
&#xD;
          -  Voluntary written consent to take part to the study&#xD;
&#xD;
          -  Serum Creatinine &lt; 2.0 mg/dL and/or Creatinine clearance or calculated Creatinine&#xD;
             clearance &gt; 40 mL/minute&#xD;
&#xD;
          -  Total bilirubin must be &lt; 2.0 x the upper limit of normal (ULN) unless known Gilbert&#xD;
             syndrome&#xD;
&#xD;
          -  ALT or AST must be &lt; 3 x the upper limit of normal.&#xD;
&#xD;
          -  Female patients: if postmenopausal for at least 1 year before enrolment or, if fertile&#xD;
             - agreeing to practice 2 effective methods of contraception or agreeing to practice&#xD;
             true abstinence.&#xD;
&#xD;
          -  Male patients should agree to practice barrier contraception or to practice abstinence&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Composite lymphoma or nodular lymphocyte-predominant Hodgkin lymphoma;&#xD;
&#xD;
          -  Bulky disease (Lugano 2014 definition: single or conglomerated nodal mass with the&#xD;
             largest diameter measuring 10 or more centimeters);&#xD;
&#xD;
          -  B symptoms;&#xD;
&#xD;
          -  Extra nodal site involved by disease;&#xD;
&#xD;
          -  Female patients who are both lactating and breastfeeding or who have a positive serum&#xD;
             pregnancy test during the screening period or a positive pregnancy test on Day 1&#xD;
             before first dose of study drug;&#xD;
&#xD;
          -  Uncompensated diabetes mellitus requiring insulin therapy;&#xD;
&#xD;
          -  Any serious medical or psychiatric illness that could, in the investigator's opinion,&#xD;
             potentially interfere with the completion of treatment according to this protocol;&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) infection with a positive search for HIV&#xD;
             antigens by immunoblot and/or circulating copies of HIV-RNA;&#xD;
&#xD;
          -  Active hepatitis B with circulating copies of HBV-DNA, or active hepatitis C infection&#xD;
             with circulating copies of HCV-RNA;&#xD;
&#xD;
          -  Severely impaired, lung and renal function;&#xD;
&#xD;
          -  Diagnosed or treated for another malignancy within 3 years before the first dose or&#xD;
             previously diagnosed with another malignancy and have any evidence of residual&#xD;
             disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are&#xD;
             not excluded if they have undergone complete resection;&#xD;
&#xD;
          -  Active autoimmune disorder in treatment with immunosuppressive drugs&#xD;
&#xD;
          -  A left-ventricular ejection fraction &lt; 50%;&#xD;
&#xD;
          -  Myocardial infarction within 2 years of study entry.&#xD;
&#xD;
          -  Pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan M Zaucha, Professor, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Gdansk</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andrea Gallamini, Professor, PhD, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research and Clinical Innovation Department of the Lacassagne Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan M Zaucha, Professor, PhD, MD</last_name>
    <phone>58 584 43 40</phone>
    <phone_ext>0048</phone_ext>
    <email>jzaucha@gumed.edu.pl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marta Bednarek, PhD</last_name>
    <phone>58 349 18 85</phone>
    <phone_ext>0048</phone_ext>
    <email>marta.bednarek@gumed.edu.pl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hematology Department IRCCS Policlinico San Matteo</name>
      <address>
        <city>Pavia</city>
        <state>P.le Golgi 19</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Gotti, MD, PhD</last_name>
      <phone>347 9797989</phone>
      <phone_ext>+39</phone_ext>
      <email>Ma.Gotti@smatteo.pv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale Papa Giovanni XXIII</name>
      <address>
        <city>Bergamo</city>
        <state>Piazza OMS, 1</state>
        <zip>24127</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Rambaldi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Via Giuseppe Ripamonti 435</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Corrado Tarella, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hematology Department Azienda Ospedaliera S. Croce e Carle</name>
      <address>
        <city>Cuneo</city>
        <state>Via Michele Coppino, 26</state>
        <zip>12100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roberto Sorasio, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <state>Via S.Pansini, 5</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Picardi, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <state>Viale Orazio Flacco, 65</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Attilio Guarini, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Università Tor Vergata</name>
      <address>
        <city>Roma</city>
        <state>Viale Oxford, 81</state>
        <zip>00133</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Maria Cantonetti, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero - Universitaria Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Gini, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera G. Brotzu - Ospedale Businco</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Giorgio La Nasa, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Divisione Universitaria di Onco-Ematologia</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Silvia Bolis, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova Dipartimento di Medicina Interna</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Livio Trentin, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedali Riuniti Villa Sofia</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Caterina Patti, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gdański Uniwersytet Medyczny Department of Hematology and Transplantology</name>
      <address>
        <city>Gdańsk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan M Zaucha, Professor, PhD, MD</last_name>
      <phone>58 584 43 40</phone>
      <phone_ext>0048</phone_ext>
      <email>jzaucha@gumed.edu.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny Zakład Opieki Zdrowotnej Szpital Uniwersytecki w Krakowie</name>
      <address>
        <city>Kraków</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Agnieszka Giza, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instytut Hematologii i Transfuzjologii ul. Indiry Gandhi 14 02-776 Warszawa</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ewa Paszkiewicz-Kozik, PhD, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uniwersyteckie Centrum Kliniczne im. Jana Mikulicza- Radeckiego we Wrocławiu</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tomasz Wrobel, Professor, PhD, MD</last_name>
      <phone>71 7841764</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Av. Roma</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ana Pilar Gonzales Rodriguez, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <state>Avda De Córdoba</state>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonia Rodriguez-Izquierdo</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynals. Institut Catala d'Oncologia</name>
      <address>
        <city>Barcelona</city>
        <state>Avinguda De La Granvia De l'Hospitalet, 199-203</state>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eva Domingo Domenech, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol-ICO Badalona</name>
      <address>
        <city>Carretera De Canyet</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Miriam Moreno Velazquez, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall d'Hebron</name>
      <address>
        <city>Passeig De La Vall d'Hebron, 119-129</city>
        <state>Barcelona</state>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cecilia Carpio, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <state>C. De Villarroel, 170</state>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carmen Martinez Munoz, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañon</name>
      <address>
        <city>Madrid</city>
        <state>Calle Del Dr. Esquerdo</state>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mariana Bastos-Oreiro, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Ramón y Cajal</name>
      <address>
        <city>Madrid</city>
        <state>Ctra. De Colmenar Viejo Km. 9,100</state>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francisco Javier Lopez Jimenez, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <state>P.º De San Vicente, 58</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Roman Garcia Sanz, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Marques de Valdecilla</name>
      <address>
        <city>Av. De Valdecilla, 25</city>
        <state>Santander</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Javier Nuñez Cespedes, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio</name>
      <address>
        <city>Av. Manuel Siurot</city>
        <state>Sevilla</state>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jorge Rodríguez Garcia, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 30, 2021</study_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

